Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke
Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV clinical trial of Repatha® (evolocumab), will be presented at the American Heart Association Scientific Sessions taking place November 7-10, 2025, in New Orleans, LA.
Results from the landmark Phase 3 VESALIUS-CV clinical trial of Repatha in patients at high cardiovascular risk without prior heart attack or stroke will be shared during the late-breaking scientific session, "Groundbreaking Trials in Cardiometabolic Therapeutics" on Saturday, November 8 at 9:10 a.m. CST (Abstract #LBS.01). It was announced in October 2025 that the trial met its dual primary endpoints demonstrating that Repatha is the first and only PCSK9 inhibitor to significantly reduce the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke.